Adaptimmune Annual report pursuant to Section 13 and 15(d)

Other current assets

12 Months Ended

Dec. 31, 2023

Note 5 — Other current assets

Other current assets consisted of the following (in thousands):


	December 31,		December 31,
	2023		2022
Research and development credits receivable	$	46,098	$	30,162
Prepayments		9,954		9,472
Clinical materials		1,329		1,279
VAT receivable		—		490
Other current assets		2,412		1,927
	$	59,793	$	43,330

On January 19, 2024, a receipt of £24.2 million ($30.8 million) was received from HMRC relating to the Research and development credits receivable.